Literature DB >> 30044007

Nonfunctioning adrenal incidentaloma: A novel predictive factor for metabolic syndrome.

Emanuela M Ribeiro Cavalari1, Marcela P de Paula1, Mariana Arruda1, Nathália Carraro1, Arthur Martins1, Kamila de Souza1, Maria C Coelho1,2, Nathalie Anne de Oliveira E Silva de Morais1,2, Aline B Moraes1, Leonardo Vieira Neto1.   

Abstract

CONTEXT: Although metabolic syndrome has been studied in patients with autonomous cortisol secretion, there are limited data for those with nonfunctioning adrenal incidentaloma (NFAI).
OBJECTIVE: To assess metabolic syndrome frequency in NFAI patients and controls without adrenal adenoma according to World Health Organization (WHO), National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III), American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) and International Diabetes Federation (IDF) criteria.
DESIGN: Retrospective and transversal study. PATIENTS: Seventy-four NFAI and 90 controls were evaluated. NFAI diagnosis was established according to current guidelines. The control group was selected based on normal adrenal imaging examinations. MEASUREMENTS: Subjects were categorized by metabolic syndrome presence according to WHO, NCEP-ATP III, AACE/ACE and IDF.
RESULTS: Age, gender, ethnicity, body mass index, smoking, menopause, statin and fibrate use were comparable between patients and controls. The frequency of prediabetes, dyslipidaemia and hypertension as well as waist circumference were significantly higher in the NFAI patients compared to the controls. The metabolic syndrome frequency in the NFAI group was significantly higher compared to the normal adrenal group: WHO: 69.2% × 31.0% (P < 0.001); NCEP-ATP III: 81.7% × 44.9% (P < 0.001); AACE/ACE: 77.1% × 31.9% (P < 0.001); IDF: 78.6% × 45.5% (P < 0.001). Logistic regression analysis showed that NFAI was a predictor of metabolic syndrome according to WHO (P = 0.001), NCEP-ATP III (P = 0.005) and AACE/ACE (P = 0.007).
CONCLUSIONS: Metabolic syndrome is frequently found in patients with NFAI, and this frequency is higher in NFAI patients than in those with normal adrenal imaging.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  adrenal adenoma; adrenal incidentaloma; metabolic syndrome; nonfunctioning adrenal incidentaloma

Mesh:

Year:  2018        PMID: 30044007     DOI: 10.1111/cen.13822

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Evaluation of body composition using dual-energy X-ray absorptiometry in patients with non-functioning adrenal incidentalomas and an intermediate phenotype: Is there an association with metabolic syndrome?

Authors:  A B Moraes; E M R Cavalari; M P de Paula; M Arruda; D S C Curi; R A Leitão; L M C de Mendonça; M L F Farias; M Madeira; L Vieira Neto
Journal:  J Endocrinol Invest       Date:  2018-11-21       Impact factor: 4.256

2.  Biochemical and clinical characteristics of patients with primary aldosteronism: Single centre experience.

Authors:  Nataša Vujačić; Ivan Paunović; Aleksandar Diklić; Vladan Živaljević; Nikola Slijepčević; Nevena Kalezić; Mirjana Stojković; Miloš Stojanović; Biljana Beleslin; Miloš Žarković; Jasmina Ćirić
Journal:  J Med Biochem       Date:  2020-01-23       Impact factor: 3.402

3.  Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma.

Authors:  Gamze Akkuş; Isa Burak Güney; Fesih Ok; Mehtap Evran; Volkan Izol; Şeyda Erdoğan; Yıldırım Bayazıt; Murat Sert; Tamer Tetiker
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

4.  Malignancy Risk and Hormonal Activity of Adrenal Incidentalomas in a Large Cohort of Patients from a Single Tertiary Reference Center.

Authors:  Ewa Cyranska-Chyrek; Ewelina Szczepanek-Parulska; Michal Olejarz; Marek Ruchala
Journal:  Int J Environ Res Public Health       Date:  2019-05-27       Impact factor: 3.390

5.  Health-related quality of life in patients undergoing adrenalectomy: report from a Swedish National Audit.

Authors:  Lo Hallin Thompson; Erik Nordenström; Martin Almquist; Anders Bergenfelz
Journal:  Langenbecks Arch Surg       Date:  2019-11-26       Impact factor: 3.445

6.  Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.

Authors:  Marta Araujo-Castro; Paola Parra Ramírez; Cristina Robles Lázaro; Rogelio García Centeno; Paola Gracia Gimeno; Mariana Tomé Fernández-Ladreda; Miguel Antonio Sampedro Núñez; Mónica Marazuela; Héctor F Escobar-Morreale; Pablo Valderrabano
Journal:  J Clin Med       Date:  2021-11-25       Impact factor: 4.241

7.  A retrospective study on the association between urine metanephrines and cardiometabolic risk in patients with nonfunctioning adrenal incidentaloma.

Authors:  Mirko Parasiliti-Caprino; Chiara Lopez; Martina Bollati; Fabio Bioletto; Chiara Sola; Maria Chiara Di Carlo; Federico Ponzetto; Iacopo Gesmundo; Fabio Settanni; Ezio Ghigo; Giulio Mengozzi; Mauro Maccario; Roberta Giordano
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

8.  The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients' stratification by body mass index and age.

Authors:  Ana Podbregar; Andrej Janez; Katja Goricar; Mojca Jensterle
Journal:  BMC Endocr Disord       Date:  2020-07-31       Impact factor: 2.763

9.  WFUMB position paper on the management incidental findings: adrenal incidentaloma.

Authors:  Christoph F Dietrich; Jean Michel Correas; Yi Dong; Christian Nolsoe; Susan Campbell Westerway; Christian Jenssen
Journal:  Ultrasonography       Date:  2019-07-09

10.  Impact of Adrenalectomy on Morbidity in Patients with Non-Functioning Adrenal Cortical Tumours, Mild Hypercortisolism and Cushing's Syndrome as Assessed by National and Quality Registries.

Authors:  Lo Hallin Thompson; Jonas Ranstam; Martin Almquist; Erik Nordenström; Anders Bergenfelz
Journal:  World J Surg       Date:  2021-06-27       Impact factor: 3.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.